NovelWise Announces First Patient Dosed in Phase Ib/II Trial of NBM-BMX for Metastatic Uveal Melanoma

San Diego, California/ Taipei, Taiwan — December 15, 2025

NovelWise Pharmaceutical Corporation today announced the initiation of patient dosing in the Company’s Phase Ib/II clinical trial of NBM-BMX, a selective HDAC8 inhibitor, for metastatic uveal melanoma (mUM) in the United States. The first patient received the NBM-BNX on December 12 at the Sarah Cannon Research Institute (SCRI) in Tennessee.

The study is being conducted at leading sites, including SCRI, where the first patient was treated by Dr. Meredith McKean, Director of the Melanoma and Skin Cancer Research Program at SCRI and a member of the BRIDGE Program Executive Committee. Dr. McKean is widely recognized for her leadership and research in ocular melanoma and cutaneous oncology.

NBM-BMX received Fast Track Designation from the U.S. Food and Drug Administration in October 2025, followed by Orphan Drug Designation in November 2025. Achievement of the first patient dosing represents a significant clinical milestone, further advancing the development of this promising therapeutic candidate.

Metastatic uveal melanoma is a rare and highly aggressive cancer with limited treatment options. NovelWise will continue to activate additional clinical sites and expand patient enrollment, working closely with investigators and regulatory agencies to accelerate the development of NBM-BMX for patients in need.